Pelthos Therapeutics Inc.(PTHS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,825 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PTHS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Pelthos Therapeutics Inc. (PTHS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTHS at 17.5/100 on a 32-signal composite quality model, placing it at rank #2,825 of 2,961 stocks — the bottom half of the AI-ranked universe. PTHS scores in the top quartile across institutional flow (84.2). Areas of concern include balance sheet strength (0.9) and profitability (5.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Pelthos Therapeutics Inc. reports quarterly revenue of $15.6M, net income of $-23.4M, free cash flow of $-7.7M. Top institutional holders of PTHS by reported 13-F value include AIGH Capital Management, Murchinson Ltd., Ikarian Capital, based on the most recent SEC filings. PTHS trades on the NYSE exchange and files with the SEC under CIK 1919246. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTHS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pelthos Therapeutics Inc. directly from SEC EDGAR. Pelthos Therapeutics Inc.'s 13F Pro composite quality score has ranged between 17 and 30 since 2026, currently 17.5 — a declining long-term trajectory across 27 quarterly and live scoring snapshots.
Revenue
Q2 2026
$15.6M
Net Income
Q2 2026
$-23.4M
Free Cash Flow
Q2 2026
$-7.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-444.6% YoYOperating Income
-328.3% YoYEPS (Diluted)
-1514.6% YoYTotal Assets
+9425.0% YoYOp. Cash Flow
-290.0% YoYFree Cash Flow
-291.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.8M | $0.00 | — | — | — |
| Net Income | $-43.3M -444.6% | $-8.0M -7.8% | $-7.4M -200.2% | $-2.5M | — |
| Operating Income | $-32.4M -328.3% | $-7.6M -10.3% | $-6.9M -196.0% | $-2.3M | — |
| EPS (Diluted) | $-23.04 -1514.6% | $-1.43 -146.9% | $-0.58 | — | — |
| Total Assets | $130.4M +9425.0% | $1.4M +1320.3% | $96.4K +75.0% | $55.1K | — |
| Operating Cash Flow | $-22.6M -290.0% | $-5.8M -490.4% | $-981.0K +37.4% | $-1.6M | — |
| Free Cash Flow | $-22.7M -291.7% | $-5.8M | — | — | — |
Get alerted when PTHS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pelthos Therapeutics Inc. including:
Top Institutional Holders of PTHS
AIGH Capital Management LLC
$9.3M329,098 shMurchinson Ltd.
$8.6M304,302 shIkarian Capital, LLC
$7.3M256,598 shBOOTHBAY FUND MANAGEMENT, LLC
$2.9M101,976 shVANGUARD CAPITAL MANAGEMENT LLC
$2.7M97,134 shCANTOR FITZGERALD, L. P.
$1.1M38,123 shJ. Goldman & Co LP
$1.1M38,075 shDIADEMA PARTNERS LP
$700.1K24,773 shWEXFORD CAPITAL LP
$632.0K22,364 shKnott David M Jr
$623.8K22,073 sh
| Fund | Value | Shares |
|---|---|---|
| AIGH Capital Management LLC | $9.3M | 329,098 |
| Murchinson Ltd. | $8.6M | 304,302 |
| Ikarian Capital, LLC | $7.3M | 256,598 |
| BOOTHBAY FUND MANAGEMENT, LLC | $2.9M | 101,976 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.7M | 97,134 |
| CANTOR FITZGERALD, L. P. | $1.1M | 38,123 |
| J. Goldman & Co LP | $1.1M | 38,075 |
| DIADEMA PARTNERS LP | $700.1K | 24,773 |
| WEXFORD CAPITAL LP | $632.0K | 22,364 |
| Knott David M Jr | $623.8K | 22,073 |
Companies Similar to PTHS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Equillium, Inc.
BioAge Labs, Inc.
Arcus Biosciences, Inc.
Voyager Therapeutics, Inc.
Vanda Pharmaceuticals Inc.
MACROGENICS INC
Aquestive Therapeutics, Inc.
Journey Medical Corp
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PTHS on your watchlist
Track score changes the day Pelthos Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PTHS a good stock to buy?
13F Pro's AI-powered analysis of Pelthos Therapeutics Inc. (PTHS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PTHS are available on the PTHS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PTHS is classified as a small company.
Which hedge funds own PTHS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PTHS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pelthos Therapeutics Inc.'s investment landscape.